Metformin-associated lactic acidosis: Moving towards a new paradigm?
Autor: | Brandon Walsh, Mark Fineman, Thomas A. Bicsak |
---|---|
Rok vydání: | 2017 |
Předmět: |
medicine.medical_specialty
medicine.drug_class Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Phenformin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Diabetes mellitus Internal Medicine medicine 030212 general & internal medicine Intensive care medicine Acidosis Biguanide business.industry medicine.disease Metformin Surgery chemistry Lactic acidosis Causal association medicine.symptom business Kidney disease medicine.drug |
Zdroj: | Diabetes, Obesity and Metabolism. 19:1499-1501 |
ISSN: | 1462-8902 |
DOI: | 10.1111/dom.12994 |
Popis: | The history of Metformin-Associated Lactic Acidosis (MALA) is rooted in the earlier experience with phenformin, another biguanide treatment for type 2 diabetes that was removed from the market owing to a clear causal association with cases of lactic acidosis (LA). Although metformin is less problematic in this regard, metformin can and does induce lactic acidosis, and under the right circumstances it continues to present a potential risk to patients. Recent liberalization of the prescribing guidelines in the US and EU specifically regarding use in more advanced stages of Chronic Kidney Disease (CKD) have led to renewed interest in the topic of MALA, and this issue of the Journal presents two timely articles on the topic by Lalau et al. [1] and Connelly et al. [2]. |
Databáze: | OpenAIRE |
Externí odkaz: |